A compounded semaglutide shipment should be traceable to its dispensing pharmacy and accompanied by clear product and storage information. Those details matter because contamination, preparation errors and poor handling can affect medication quality.[1][2]

Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness or quality before marketing.[3]

Sterility is a preparation and handling issue

For an injectable medication, sterility concerns contamination by microorganisms. FDA has identified insanitary conditions at compounding facilities and investigated serious harm from contaminated compounded drugs.[1]

A clear-looking liquid or an intact vial does not establish how it was prepared. The relevant information comes from the pharmacy, its oversight and the procedures applicable to the preparation.

The pharmacy can explain how the product should be stored, what the label's dates mean and whom to contact if packaging or instructions are unclear. FDA identifies inadequate labeling as another potential problem with compounded products.[1]

Shipping conditions can affect quality

FDA has received complaints about compounded GLP-1 medicines arriving warm or with inadequate cooling. The agency advises against using injectable GLP-1 drugs that arrive warm or without sufficient refrigeration because quality may be affected.[2]

That makes a delivery problem a question for the dispensing pharmacy, not something to resolve by guessing from another product's instructions. Refrigerating a questionable shipment after arrival does not answer what happened in transit.

The product's own storage information and the pharmacy's response should address the specific shipment.

After a multidose vial is first used

FDA recommends discarding multidose vials of compounded GLP-1 medication within 28 days after first use, even if medication remains or the compounder gives a longer period. Each dose requires a new sterile needle and syringe.[2]

The label should make the prescription understandable

Different concentrations and vial presentations can create confusion. FDA has received reports of serious errors involving measurement of compounded semaglutide, including errors by patients and health professionals.[2]

The prescribed instructions, product concentration and supplied measuring equipment need to be clear together. This is a point for direct clarification with the prescriber or pharmacist; an online conversion example is not a substitute for that clarification.

Keep the contact details with the order

The pharmacy's name, label, packaging information and order record help identify the preparation if a question arises later. FDA also accepts reports of medication-related adverse events and quality problems through MedWatch.[2]